Suppr超能文献

Pirh2 RING-finger E3 泛素连接酶:在肿瘤发生和癌症治疗中的作用。

Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.

机构信息

Comparative Oncology Laboratory, University of California, Davis, CA 95616, USA.

出版信息

FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3.

Abstract

The ubiquitin-dependent proteasome system plays a critical role in many cellular processes and pathogenesis of various human diseases, including cancer. Although there are a large number of E3 ubiquitin ligases, the majority are RING-finger type E3s. Pirh2, a target of p53 transcription factor, contains a highly conserved C(3)H(2)C(3) type RING domain. Importantly, Pirh2 was found to regulate a group of key factors dedicated to the DNA damage response, such as p53, p73, PolH, and c-Myc. Interestingly, Pirh2 was upregulated or downregulated in different types of cancers. These suggest that Pirh2 is implicated in either promoting or suppressing tumor progression in a tissue-dependent manner. This review will focus on the major findings in these studies and discuss the potential to explore Pirh2 as a cancer therapeutic target.

摘要

泛素依赖的蛋白酶体系统在许多细胞过程和各种人类疾病(包括癌症)的发病机制中起着关键作用。虽然有大量的 E3 泛素连接酶,但大多数是 RING 指型 E3s。Pirh2 是 p53 转录因子的靶标,含有高度保守的 C(3)H(2)C(3)型 RING 结构域。重要的是,发现 Pirh2 调节一组专门用于 DNA 损伤反应的关键因子,如 p53、p73、PolH 和 c-Myc。有趣的是,Pirh2 在不同类型的癌症中上调或下调。这些表明 Pirh2 以组织依赖的方式参与促进或抑制肿瘤进展。这篇综述将重点介绍这些研究中的主要发现,并讨论将 Pirh2 作为癌症治疗靶点的潜力。

相似文献

1
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3.
3
Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.
J Biol Chem. 2011 Feb 11;286(6):4796-808. doi: 10.1074/jbc.M110.157669. Epub 2010 Nov 17.
4
Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
Mol Biol Rep. 2011 Jan;38(1):229-36. doi: 10.1007/s11033-010-0099-x. Epub 2010 Mar 24.
5
The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
J Biol Chem. 2011 Oct 14;286(41):35388-35395. doi: 10.1074/jbc.M111.261537. Epub 2011 Aug 18.
6
A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Int J Cancer. 2013 Dec 15;133(12):2759-68. doi: 10.1002/ijc.28129. Epub 2013 Mar 25.
7
Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation.
Mol Cell Biol. 2010 Feb;30(4):1041-8. doi: 10.1128/MCB.01198-09. Epub 2009 Dec 14.
8
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
PLoS Genet. 2011 Nov;7(11):e1002360. doi: 10.1371/journal.pgen.1002360. Epub 2011 Nov 17.
9
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Exp Cell Res. 2006 Oct 15;312(17):3370-8. doi: 10.1016/j.yexcr.2006.07.005. Epub 2006 Jul 21.
10
Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1.
Cancer Res. 2007 Nov 15;67(22):10789-95. doi: 10.1158/0008-5472.CAN-07-2033.

引用本文的文献

2
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.
Aging Dis. 2024 Apr 1;15(2):640-697. doi: 10.14336/AD.2023.0520.
3
Recognition of an Ala-rich C-degron by the E3 ligase Pirh2.
Nat Commun. 2023 Apr 29;14(1):2474. doi: 10.1038/s41467-023-38173-6.
4
The Role of E3 Ligase Pirh2 in Disease.
Cells. 2022 Apr 30;11(9):1515. doi: 10.3390/cells11091515.
5
RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma.
Oncogene. 2022 Apr;41(16):2275-2286. doi: 10.1038/s41388-022-02247-4. Epub 2022 Mar 2.
8
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.
J Hematol Oncol. 2021 Aug 9;14(1):121. doi: 10.1186/s13045-021-01111-4.
9
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.
Cell Death Dis. 2021 Jun 5;12(6):581. doi: 10.1038/s41419-021-03871-w.
10

本文引用的文献

1
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
PLoS Genet. 2011 Nov;7(11):e1002360. doi: 10.1371/journal.pgen.1002360. Epub 2011 Nov 17.
2
Structure and kinetic stability of the p63 tetramerization domain.
J Mol Biol. 2012 Jan 20;415(3):503-13. doi: 10.1016/j.jmb.2011.11.007. Epub 2011 Nov 12.
3
Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination.
Mol Cancer Res. 2011 Dec;9(12):1780-90. doi: 10.1158/1541-7786.MCR-11-0157. Epub 2011 Oct 12.
5
The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
J Biol Chem. 2011 Oct 14;286(41):35388-35395. doi: 10.1074/jbc.M111.261537. Epub 2011 Aug 18.
6
Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis.
Mol Cell Biol. 2011 Oct;31(19):3997-4006. doi: 10.1128/MCB.05808-11. Epub 2011 Jul 26.
7
AIG1 is a novel Pirh2-interacting protein that activates the NFAT signaling pathway.
Front Biosci (Elite Ed). 2011 Jun 1;3(3):834-42. doi: 10.2741/E291.
8
Proteasome inhibitors in cancer therapy.
J Cell Commun Signal. 2011 Jun;5(2):101-10. doi: 10.1007/s12079-011-0121-7. Epub 2011 Jan 31.
10
A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination.
FEBS Lett. 2010 Aug 4;584(15):3275-8. doi: 10.1016/j.febslet.2010.06.027. Epub 2010 Jun 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验